Methodological considerations in quantification of oncological FDG PET studies.
about
Meditative music listening to reduce state anxiety in patients during the uptake phase before positron emission tomography (PET) scans.Optimal Modality for Detecting Distant Metastasis in Primary Nasopharyngeal Carcinoma during Initial Staging: A Systemic Review and Meta-analysis of 1774 PatientsIntra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.FDG-PET Response Prediction in Pediatric Hodgkin's Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value.Can Parameters Other than Minimal Axial Diameter in MRI and PET/CT Further Improve Diagnostic Accuracy for Equivocal Retropharyngeal Lymph Nodes in Nasopharyngeal Carcinoma?Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma.Simultaneous PET-MRI in oncology: a solution looking for a problem?Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake timesPositron emission tomography imaging approaches for external beam radiation therapies: current status and future developmentsRecommendations for the use of PET and PET-CT for radiotherapy planning in research projectsHarmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful.Clinical applications of positron emission tomography in sarcoma management.The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature.Initial experience of MR/PET in a clinical cancer center.Repeatability of the Maximum Standard Uptake Value (SUVmax) in FDG PET.18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods.Dual nano-sized contrast agents in PET/MRI: a systematic review.Comparison of Bayesian penalized likelihood reconstruction versus OS-EM for characterization of small pulmonary nodules in oncologic PET/CT.Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis.Guidelines for quality control of PET/CT scans in a multicenter clinical studyDiffuse intra-abdominal splenosis presenting as carcinomatosis exhibiting positron emitted tomography hypermetabolic activity.Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome.Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT.The use of zeolites to generate PET phantoms for the validation of quantification strategies in oncology.Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma.A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy.SUV-measurements and patient-specific corrections in pediatric Hodgkin-lymphoma: is there a benefit for PPV in early response assessment by FDG-PET?Feasibility of state of the art PET/CT systems performance harmonisation.Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer.
P2860
Q30395762-8E7B37B4-93D1-4B73-85F9-26DFF6E70120Q33776738-3AC5C37F-1B7C-4434-AB23-949C6A743BCCQ33841547-1BBB9D24-8B6F-4BB7-BBA1-8D4444EBE0CBQ35237507-90CD9888-B1AE-4D14-8E06-D6C132D5F5F1Q36162670-D1E3D201-7329-4A66-AD94-6ECCB2F2A319Q36205152-FC165A70-AE8C-4058-A670-622E436852EDQ36303648-BD0A4CBE-6D7E-4FEA-BD2B-6620DA9D324FQ36304366-624656FD-F27D-4069-8334-102598A75945Q36325435-C56D06FB-7AF1-43D5-BCE2-8D8B0EEC32AAQ36653233-C3922F22-0143-4B4A-8066-61BD2F406D80Q36920672-FC787811-2051-4220-993F-9E2B43C70FBDQ37240835-E3828D48-C5A6-47E2-A769-12C0BCA9551FQ37589543-C38D4DFA-1556-42F4-A11B-F4B2B12EDCDAQ37845828-6F6F0FD8-C5E8-4954-96CA-B68A495DE987Q37857025-31164266-FBC6-451A-BF92-3869D45650C8Q38134357-7367E92F-1134-4C55-993B-C5A6C9077C75Q38327306-9FD59183-A856-461C-A0B2-1D1D5A06701BQ39000737-37994500-6010-41C8-999A-C6264C21A457Q39013112-841F8911-6A60-4E1F-BC21-76D57CEB8269Q39423472-B2590703-78C0-4EED-ADAA-915171666CDAQ41521598-2E154F2D-FD66-4D90-AB68-BF963595721AQ41683890-018DB3D5-8DD5-446F-9520-6BDE0DB2D29FQ42796864-677029B9-6CC2-42B2-A5A8-F87E561398B6Q43491287-1609762A-AFE4-47BE-BE2A-CF6445DE765FQ43517997-C5A16AC3-DA94-4801-9511-0919C2D90097Q45276235-5ADA3601-1902-477F-974D-F7E36BD6361BQ50894106-DC9812D9-071F-4309-A8AE-CFEB1E1286B2Q50896674-59656B2F-7FBF-4300-9111-0DEEC8A3EE51Q51373515-86572738-9FD8-4646-AE50-B21FC2475972Q52676354-3F7B566D-B4FB-4E74-B829-60F11EC06F26Q55252177-0F1BC738-8D87-476B-A52D-F6CEE4CCE296
P2860
Methodological considerations in quantification of oncological FDG PET studies.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Methodological considerations in quantification of oncological FDG PET studies.
@ast
Methodological considerations in quantification of oncological FDG PET studies.
@en
type
label
Methodological considerations in quantification of oncological FDG PET studies.
@ast
Methodological considerations in quantification of oncological FDG PET studies.
@en
prefLabel
Methodological considerations in quantification of oncological FDG PET studies.
@ast
Methodological considerations in quantification of oncological FDG PET studies.
@en
P2860
P50
P1476
Methodological considerations in quantification of oncological FDG PET studies
@en
P2093
Eric P Visser
P2860
P2888
P304
P356
10.1007/S00259-009-1306-7
P577
2009-11-20T00:00:00Z